Skip to content

Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study

Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02862808
Acronym
SHD-DI
Enrollment
18
Registered
2016-08-11
Start date
2019-03-15
Completion date
2019-12-03
Last updated
2020-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Intellectual Disability

Keywords

Whole exome sequencing, Molecular diagnostic, Genetic counselling

Brief summary

Evaluation of diagnostic whole exome sequencing in patients with syndromic or isolated severe intellectual disability without a molecular diagnostic, with suspected autosomal recessive inheritance, allowing accurate genetic counseling in this high risk of recurrence group of diseases

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of syndromic or isolated severe intellectual disability (IQ \<50) without a molecular diagnosis * Recurrence in siblings (multiplex families) suggesting autosomal recessive inheritance (with or without parental consanguinity) or sporadic cases from a consanguineous union * Conventional genetic tests performed (including array-CGH) and MRI/CT-scan available * DNA samples from parents and from both unaffected or affected siblings available, for parental segregation and confirmation of candidate variations identified. * Availability of a signed informed consent * To be affiliated or beneficiary of French social security/healthcare system

Exclusion criteria

* Parents in the exclusion period of another study or as provided by the national register of volunteers * High-probability diagnostic hypothesis for which a molecular test is available at lower cost than exome sequencing

Design outcomes

Primary

MeasureTime frame
Number of patients with a molecular diagnostic and diagnostic yieldup to 12 months

Secondary

MeasureTime frame
Cost/diagnostic ratio in comparison with conventional techniquesup to 12 months
Reporting time in comparison with conventional techniquesup to 12 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026